A cyclooxygenase-2 promoter-based conditionally replicating adenovirus with enhanced infectivity for treatment of ovarian adenocarcinoma.
about
Systemic therapy for cervical cancer with potentially regulatable oncolytic adenovirusesPreclinical evaluation of transcriptional targeting strategies for carcinoma of the breast in a tissue slice model systemConditionally replicating adenovirus expressing TIMP2 increases survival in a mouse model of disseminated ovarian cancerOncolytic immunotherapy: where are we clinically?Role of RGD-containing ligands in targeting cellular integrins: Applications for ovarian cancer virotherapy (Review)Tissue-specific promoters for cancer gene therapy.Adenoviruses for treatment of cancer.A tumor-stroma targeted oncolytic adenovirus replicated in human ovary cancer samples and inhibited growth of disseminated solid tumors in mice.Advanced generation adenoviral virotherapy agents embody enhanced potency based upon CAR-independent tropismGene therapy of gynaecological diseases.Oncolytic adenoviral gene therapy in ovarian cancer: why we are not wasting our time.Oncolytic virotherapy with modified adenoviruses and novel therapeutic targets.Integrin targeted oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors.Ad5/3-9HIF-Delta24-VEGFR-1-Ig, an infectivity enhanced, dual-targeted and antiangiogenic oncolytic adenovirus for kidney cancer treatment.Tetracycline-inducible promoter-based conditionally replicative adenoviruses for the control of viral replication.Sodium iodide symporter-mediated radioiodide imaging and therapy of ovarian tumor xenografts in mice.Complex mosaicism is a novel approach to infectivity enhancement of adenovirus type 5-based vectors.A three-dimensional assay for measurement of viral-induced oncolysis.Human dendritic cells infected with an adenoviral vector suppress proliferation of autologous and allogeneic T cells.
P2860
Q21144267-430F2AB5-EADC-4BA5-8081-D8E6EEBCFC6CQ25257352-B5BD5E78-2263-426D-9D26-300645E272FEQ34055529-1E36B889-6673-47E5-B133-9D04E0DE6764Q34405325-819CC067-CBAC-4726-BB57-6D71139A5344Q34433546-896E1DA7-443C-496E-AABC-A8A1AAAA2E23Q35779378-C67D28FE-6AE2-4D98-8EE1-DB868967AF09Q36132288-83CC8FBF-B7F4-4D37-9684-07A4E16A6618Q36460449-5C1F4C89-760F-4662-B561-891622FEE924Q36468656-6D14EB1F-8280-47BC-B687-1DC3E15F5615Q36922247-312AA791-D542-4880-8261-6A20F53358FCQ37448942-CE069EC1-9212-4D68-B6FA-C7777E9FB1DBQ38033591-5DFCC02E-A6B2-4011-AD6D-78D70EB63095Q39532576-4BAA4302-2D1E-4EFC-AD2C-52B25070F7D0Q39851910-D822FBA7-FFB2-4140-B3CC-7907F025F649Q39894493-AEDC51CC-0539-42A1-BC9A-1FF8F3A59724Q40381616-9507AB9E-768E-4396-A1F2-5E6BBCB0E606Q40459504-EAE23CDE-8A0D-4DC0-AC47-5FCCBB2728D1Q41813055-3D7B1214-90DA-4338-A975-487D36987095Q47677023-E51F6F91-B001-41EF-80DB-E06E8C094C4C
P2860
A cyclooxygenase-2 promoter-based conditionally replicating adenovirus with enhanced infectivity for treatment of ovarian adenocarcinoma.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
A cyclooxygenase-2 promoter-ba ...... ent of ovarian adenocarcinoma.
@en
type
label
A cyclooxygenase-2 promoter-ba ...... ent of ovarian adenocarcinoma.
@en
prefLabel
A cyclooxygenase-2 promoter-ba ...... ent of ovarian adenocarcinoma.
@en
P2093
P2860
P356
P1433
P1476
A cyclooxygenase-2 promoter-ba ...... ent of ovarian adenocarcinoma.
@en
P2093
Alvarez RD
Bauerschmitz GJ
Hemminki A
Yamamoto M
P2860
P2888
P304
P356
10.1038/SJ.GT.3302181
P577
2004-03-01T00:00:00Z
P5875
P6179
1008538052